Access Update- #24

We hope you acted quickly on our latest recommendation issued Friday, to buy ViroPharma (Nasdaq: VPHM).

The stock is up this morning after the company reported strong second quarter results. VPHM earned $0.30 cents per share on revenue of $65.4 million. Wall Street had projected an EPS of $0.26 on sales of $58.9M

Importantly, the company raised sales guidance for the full year, to a range of $220 million – $240 million. The consensus forecast was $213.2 million. Our estimate was $219.8 million. We are updating our earnings model and will let you know if our estimates change.

The company did not break any new ground regarding the threat of generic Vancocin. Management is optimistic that they will get the chance to present clinical and scientific data to the FDA, regarding why generic Vancocin should not be approved based on in vitro bioequivalence.

Conference Call Next Week

Our conference call with VPHM will be on Wednesday, August 6th at 2:00 p.m. EST, 1:00 p.m. CT and 11:00 a.m. PT. Participants on the call will include VPHM CEO Vincent Milano, COO Dan Soland and Chief Scientific Officer Dr. Colin Broom.

We have an exciting new development for this call. Subscribers will now be able to submit questions live through the webcast console. Details on how to listen to the call, view the webcast and submit questions will be provided shortly.

In the meantime, please read the report and feel free to submit your questions ahead of time via email .

For those of you who will not be able to listen to the call live, an archive will be posted on our website shortly after.

New Recommendation in August

If you were to ask me which of our stocks in our portfolio is my favorite, I couldn’t give you an answer. It would be like asking which of my children do I like best.

However, I think I’m about to play favorites with a small oncology company that I will reveal to you in August. Their lead drug candidate has worked effectively in well-designed clinical trials, they would have a lucrative market to themselves, and they’ve got plenty of cash. I anticipate the report will be issued in about three to four weeks.

I’ll be back to you in a day or so with the details on the VPHM call.

Marc Lichtenfeld
Director of Research
Access Research Group

Stock
Symbol
Current Price
Comments

ViroPharma

VPHM

$11.77

Buy up to $12.50

Cytori Therapeutics

CYTX

$7.29

Buy up to $8

Electro-OpticalSciences

MELA

$6.18

Buy up to $5.75